Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $7.77M | $10.1M | $13.1M |
| Revenue growth | — | — | — | — | — | — | — | — | 29.9% | 29.8% |
| Operating income | -$39.0M | -$21.3M | -$26.3M | -$28.8M | -$50.5M | -$92.3M | -$112M | -$118M | -$137M | -$126M |
| Operating margin | — | — | — | — | — | — | — | -1523.9% | -1354.3% | -959.1% |
| Net income | -$38.8M | -$21.1M | -$26.1M | -$28.6M | -$50.5M | -$92.3M | -$110M | -$117M | -$130M | -$124M |
| Net margin | — | — | — | — | — | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (diluted) | -$15.41 | -$31.69 | -$259.85 | -$19.33 | -$0.55 | -$8.10 | -$20.01 | -$14,720.25 | -$176.60 | -$14.57 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.3M | -$19.1M | -$24.0M | -$26.7M | -$48.6M | -$75.6M | -$98.1M | -$102M | -$60.9M | -$99.8M |
| Capital expenditures | $66.0K | $5.00K | $6.00K | $17.0K | $8.56M | $35.3M | $48.1M | $7.89M | $120K | $3.37M |
| Free cash flow | -$37.4M | -$19.1M | -$24.0M | -$26.7M | -$57.1M | -$111M | -$146M | -$110M | -$61.0M | -$103M |
| Share buybacks | — | — | — | — | — | — | — | $14.0M | — | $13.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.9M | $25.5M | $25.0M | $11.2M | $77.1M | $179M | $120M | $24.9M | $98.8M | $208M |
| Total assets | $27.5M | $26.8M | $26.3M | $14.6M | $98.2M | $241M | $226M | $154M | $163M | $277M |
| Total liabilities | $2.15M | $2.14M | $2.65M | $5.14M | $10.5M | $22.2M | $18.5M | $48.9M | $23.3M | $32.0M |
| Long-term debt | — | — | — | — | — | — | — | $6.56M | $4.67M | — |
| Shareholders' equity | $25.4M | $24.6M | $23.7M | $9.42M | $87.6M | $219M | $207M | $106M | $140M | $245M |
| Retained earnings | -$141M | -$162M | -$188M | -$217M | -$268M | -$360M | -$470M | -$601M | -$731M | -$855M |
| Shares (wtd avg diluted) | 3.92M | 786K | 15.3M | 8.53M | 206M | 11.4M | 5.84M | 7.92B | 736K | 8.51M |
Every figure is extracted from Tonix Pharmaceuticals Holding Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.